



Bruno Silva-Santos is professor of Immunology and Immune-Oncology at the Faculty of Medicine, University of Lisbon (Portugal), and vice-Director and group leader at the associated Instituto de Medicina Molecular - João Lobo Antunes (iMM-JLA). As an independent group leader, he has focused on dissecting the molecular mechanisms that control the development and functional differentiation of T cell subsets; and their activation and cellular responses to infections and tumours. His translational efforts in cancer immunotherapy led him to co-found the Portuguese biotech company, Lymphact S.A., acquired in 2018 by GammaDelta Therapeutics (London, UK) and now part of Takeda Pharmaceutical Co. He has been distinguished with nominations, awards and grants from the European Molecular Biology Organization (EMBO), the European Research Council (ERC), the International Cytokine Society (ICS) and the European Academy of Tumour Immunology (EATI).